tiprankstipranks
Advertisement
Advertisement

OKYO Stock Latest News

OKYO Pharma CSO Increases Stake Ahead of Planned Phase 3 Trial
Company AnnouncementsOKYO Pharma CSO Increases Stake Ahead of Planned Phase 3 Trial
6d ago
6K
OKYO
Okyo Pharma CSO Raj Patil purchases 3,363 shares at $1.49
PremiumThe Fly
Okyo Pharma CSO Raj Patil purchases 3,363 shares at $1.49
6d ago
OKYO
OKYO Pharma to Present Late-Stage Ophthalmic Pipeline at BTIG Biotechnology Conference 2026
PremiumCompany Announcements
OKYO Pharma to Present Late-Stage Ophthalmic Pipeline at BTIG Biotechnology Conference 2026
7d ago
6K
OKYO
OKYO Pharma Director Ups Stake Ahead of Planned Phase 3 Neuropathic Corneal Pain Trial
PremiumCompany Announcements
OKYO Pharma Director Ups Stake Ahead of Planned Phase 3 Neuropathic Corneal Pain Trial
11d ago
6K
OKYO
Okyo Pharma director John Brancaccio acquires 5,000 shares at $1.38
PremiumThe Fly
Okyo Pharma director John Brancaccio acquires 5,000 shares at $1.38
11d ago
OKYO
Okyo Pharma CEO Robert Dempsey purchases 15,000 shares at $1.54
PremiumThe FlyOkyo Pharma CEO Robert Dempsey purchases 15,000 shares at $1.54
11d ago
OKYO
OKYO Pharma CEO Boosts Stake With Nasdaq Share Purchase
Premium
Company Announcements
OKYO Pharma CEO Boosts Stake With Nasdaq Share Purchase
11d ago
6K
OKYO
OKYO Pharma Chairman Boosts Stake to Over 20% Ahead of Phase 3 Trial
Premium
Company Announcements
OKYO Pharma Chairman Boosts Stake to Over 20% Ahead of Phase 3 Trial
12d ago
6K
OKYO
Okyo Pharma says Chairman Gabriele Cerrone buys 22,500 shares at $1.45/share
PremiumThe Fly
Okyo Pharma says Chairman Gabriele Cerrone buys 22,500 shares at $1.45/share
12d ago
OKYO
OKYO Pharma Executive Boosts Shareholding Ahead of Planned Phase 3 NCP Trial
PremiumCompany Announcements
OKYO Pharma Executive Boosts Shareholding Ahead of Planned Phase 3 NCP Trial
12d ago
6K
OKYO
Okyo Pharma says CDO Gary Jacob purchases 3,500 shares for $1.40 per share
PremiumThe Fly
Okyo Pharma says CDO Gary Jacob purchases 3,500 shares for $1.40 per share
12d ago
OKYO
Okyo Pharma CMO Flavio Mantelli purchases 20,000 shares at $1.40
PremiumThe Fly
Okyo Pharma CMO Flavio Mantelli purchases 20,000 shares at $1.40
12d ago
OKYO
OKYO Pharma CMO Boosts Stake Ahead of Planned Global Phase 3 Trial
PremiumCompany AnnouncementsOKYO Pharma CMO Boosts Stake Ahead of Planned Global Phase 3 Trial
12d ago
6K
OKYO
OKYO Pharma to Present Ophthalmology Pipeline Ahead of Phase 3 Urcosimod Trial
Premium
Company Announcements
OKYO Pharma to Present Ophthalmology Pipeline Ahead of Phase 3 Urcosimod Trial
13d ago
6K
OKYO
OKYO Pharma Chairman Boosts Stake Ahead of Phase 3 Neuropathic Corneal Pain Trial
Premium
Company Announcements
OKYO Pharma Chairman Boosts Stake Ahead of Phase 3 Neuropathic Corneal Pain Trial
13d ago
6K
OKYO
Okyo Pharma chairman Gabriele Cerrone buys 25,000 shares at $1.40 per share
PremiumThe Fly
Okyo Pharma chairman Gabriele Cerrone buys 25,000 shares at $1.40 per share
13d ago
OKYO
OKYO Pharma Files Annual Report and Secures Funding for Phase 3 NEPTUNE Trial
PremiumCompany Announcements
OKYO Pharma Files Annual Report and Secures Funding for Phase 3 NEPTUNE Trial
14d ago
6K
OKYO
Okyo Pharma price target lowered to $5 from $7 at H.C. Wainwright
PremiumThe Fly
Okyo Pharma price target lowered to $5 from $7 at H.C. Wainwright
21d ago
OKYO
Okyo Pharma receives feedback from FDA Type D meeting on urcosimod pathway
PremiumThe Fly
Okyo Pharma receives feedback from FDA Type D meeting on urcosimod pathway
26d ago
OKYO
OKYO Pharma Secures FDA Backing to Advance Urcosimod into Global Phase 3 Trial for Neuropathic Corneal Pain
PremiumCompany AnnouncementsOKYO Pharma Secures FDA Backing to Advance Urcosimod into Global Phase 3 Trial for Neuropathic Corneal Pain
26d ago
6K
OKYO
OKYO Pharma to Highlight Neuropathic Corneal Pain Program at Piper Sandler Virtual Ophthalmology Symposium
Premium
Company Announcements
OKYO Pharma to Highlight Neuropathic Corneal Pain Program at Piper Sandler Virtual Ophthalmology Symposium
27d ago
6K
OKYO
OKYO Pharma Adds European Eye Disease Expert to Advisory Board as Urcosimod Advances in Neuropathic Corneal Pain
Premium
Company Announcements
OKYO Pharma Adds European Eye Disease Expert to Advisory Board as Urcosimod Advances in Neuropathic Corneal Pain
3M ago
6K
OKYO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >